Efficacy and safety of tirofiban in treatment of acute coronary syndrome
XIE Yang
LIN Yu-peng
HUANG Wei-peng
Abstract：Objective To investigate the efficacy and safety of tirofiban in treatment of acute coronary syndrome (ACS). Methods ACS patients (n=92, male 61, female 31, aged from 52 to 74 and average age=62.8± 7.3) were chosen from Oct. 2011 to Apr. 2013, and randomly divided into control group and treatment group (each n=46). The control group and treatment group were given routine drugs including aspirin, low molecular weight heparin, clopidogrel and atorvastatin, and treatment group was additionally given tirofiban. The peak level of cardiac troponin I (cTnI) after treatment for 24 h, and major adverse cardiovascular events (MACE), ST-segment resolution rate, LVEF and bleeding events after treatment for 30 d were compared between 2 groups. Results The level of cTnI increased in 2 groups after treatment, and was lower in treatment group than that in control group [(1.54 ±0.52)μg/L vs. (2.24±0.48)μg/L, all P<0.01]. The incidence of MACE increased in control group compared with treatment group (15.22%vs. 2.17%, P<0.05). There were 25 cases with ST-segment resolution and resolution rate was 54.35%in control group, and there were 37 cases with ST-segment resolution and resolution rate was 80.43%(P<0.01). After treatment for 30 d, LVEF was higher in 2 groups than before (all P<0.01), and was higher in treatment group than that in control group [(58.1±5.6)% vs. (46.2±5.1)%, P<0.01]. There were 10 cases (21.74%) with skin and mucous membrane bleeding in treatment group and 7 (15.22%) in control group (P>0.05). Conclusion Routine therapy combining tirofiban in treatment of ACS can relieve myocardial cell injury, reduce incidence of MACE and improve heart function with higher safety.
Keywords：Acute coronary syndromeTirofibanSafetyEfficacy
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 368-370 )